Echeverría C, Bittar M, Bourren P, Chouela E, Galimberti R, Gusis SE, Iribas JL, Kogan N, Laffargue J, Magariños G, Maskin M, Poggio N, Raimondo N, Salazar TS, Ubogui J, Veira R, Ziella ME

Idioma: Español
Referencias bibliográficas: 82
Paginas: 145-156
Archivo PDF: 326.41 Kb.

RESUMEN

Introducción: La psoriasis es una enfermedad inflamatoria, sistémica y crónica de la piel y articulaciones. La mayoría de los pacientes reciben tratamiento subóptimo, en particular en las formas moderadas a severas. Objetivos: El objetivo principal del programa Progressive Psoriasis Initiative de Argentina fue adaptar el consenso internacional al escenario nacional. Material y métodos: Se emplearon técnicas de consenso formal y se organizaron conferencias de consenso en las que se aplicó la técnica Delphi modificada. Resultados: El grupo de expertos adoptó las definiciones consensuadas por la PPI internacional. El comité buscó adaptar las propuestas de las guías internacionales previas a la situación local buscando la mejor evidencia disponible o basándose en su práctica cotidiana para la toma de decisiones. Conclusiones: Confiamos en que esta guía pueda llegar a todo el cuerpo médico e implementarse entre los profesionales tratantes, constituyendo un marco formal de referencia en la toma de decisiones en la práctica clínica.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011; 303: 1-10.

2. Nast A, Erdmann R, Hofelich V, Reytan N, Orawa H, Sterry W et al. Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German Psoriasis Guidelines. Arch Dermatol Res. 2009; 301: 553-559.

3. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatol. 2008; 216: 366-372.

4. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M et al. Evidence-based (S3) guidelines for the treatment of Psoriasis vulgaris. JDDG: J Dtsch Dermatol Ges. 2007; 5: 1-119.

5. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res. 2007; 299: 111-138.

6. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K et al. S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012; 10: S1-s95.

7. Nast A, Augustin M, Boehncke WH, Klaus J, Mrowietz U, Ockenfels HM et al. S3-leitlinie zur therapie der psoriasis vulgaris-update: „übersicht der therapieoptionen” und “efalizumab”. J Dtsch Dermatol Ges. 2010; 8: 65-66.

8. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A et al. European S3-Guidelines on the systemic treatment of Psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009; 23: 1-70.

9. Mrowietz U, de Jong EMGJ, Kragballe K, Langley R, Nast A, Puig L et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014; 28: 438-453.

10. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000; 32: 1008-1015.

11. National Psoriasis Foundation. Secondary. https://www.psoriasis.org/recursos-en-espanol/tratamientos/sistemicos.

12. Chládek J, Simková M, Vanecková J, Hroch M, Chládkova J, Martínková J et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol. 2008;64:347-355.

13. Flytström I, Stenberg B, Svensson Å, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008; 158: 116-121.

14. Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J et al. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol. 2008; 22: 19-24.

15. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Eng J Med. 2011; 365: 1586-1596.

16. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008; 158: 549-557.

17. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008; 158: 558-566.

18. Akhyani M, Chams-Davatchi C, Hemami MR, Fateh S. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2010; 24: 1447-1451.

19. Heydendael VMR, Spuls PI, Opmeer BC, Reitsma JB, Goldschmidt WF, Bossuyt P et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Eng J Med. 2003; 349: 658-665.

20. Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011; 165: 1109-1117.

21. Berends MAM, Snoek J, De Jong EM, van de Kerkhof PC, van Oijen MG, van Krieken JH et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther. 2006; 24: 805-811.

22. Malatjalian D, Ross J, Williams C, Colwell SJ, Eastwood BJ et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol Hepatol. 1996; 10: 369-375.

23. Montaudié H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol. 2011; 25: 12-18.

24. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010; 28: 88-92.

25. Nast A, Boehncke W-H, Mrowietz U, Ockenfels HM, Philipp S, Reich K et al. S3-leitlinie zur therapie der Psoriasis vulgaris update 2011. J Dtsch Dermatol Ges. 2011; 9: S1-S104.

26. Saurat JH, Langley RG, Reich K, Unnebrink K, Sasso EH, Kampman W. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br J Dermatol. 2011; 165: 399-406.

27. Elder CA, Moore M, Chang CT, Jin J, Charnick S, Nedelman J et al. Efficacy and pharmacokinetics of two formulations of cyclosporine a in patients with psoriasis. J Clin Pharmacol. 1995; 35: 865-875.

28. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol. 1994; 31: 68-74.

29. Koo J, for the OLP302 Study Group. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol. 1998; 139: 88-95.

30. Mahrle G, Schulze HJ, Färber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol. 1995; 32: 78-88.

31. Yoon HS, Youn JI. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat. 2007; 18: 286-290.

32. Finzi AF, Mozzanica N, Pigatto PD et al. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Dermatology. 1993; 187: 8-18.

33. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol. 1994; 130: 366-375.

34. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. 2001; 145: 438-445.

35. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH et al. Cyclosporine for plaque-type psoriasis. N Eng J Med. 1991; 324: 277-284.

36. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008; 88: 1242-1247.

37. Shintani Y, Kaneko N, Furuhashi T, Saito C, Morita A et al. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis. J Dermatol. 2011; 38: 966-972.

38. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996; 132: 623-629.

39. Maza A, Montaudié H, Sbidian E, Gallini A, Aractingi S, Aubin F et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011; 25: 19-27.

40. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 year cohort study. J Invest Dermatol. 2003; 120: 211-216.

41. Kivelevitch DN, Tahhan PV, Bourren P, Kogan NN, Gusis SE, Rodríguez EA et al. Self-medication and adherence to treatment in psoriasis. Int J Dermatol. 2012; 51: 416-419.

42. Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011; 64: 671-681.

43. Driessen RJB, Van De Kerkhof PCM, De Jong EMGJ. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol. 2008; 159: 460-463.

44. Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008; 88: 495-501.

45. Gottlieb AB, Strober BE, Kricorian G et al. Adding methotrexate to etanercept versus etanercept monotherapy in adults with moderate to severe plaque psoriasis: efficacy and safety. J Am Acad Dermatol. 2011; 66: AB184.

46. Kamili QU, Miner A, Hapa A, Menter A. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review. J Drugs Dermatol. 2011; 10: 539-544.

47. Riedl E, Torzicky M, Reider N et al. Infliximab in combination with low-dose methotrexate for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2009; 60: AB170.

48. Ryan C, Kirby B, Collins P, Rogers S. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol. 2009; 34: 784-788.

49. Dai W, Moore AY. Combination regimen of acitretin and adalimumab for moderate to severe psoriasis. J Am Acad Dermatol. 2010; 62: AB132.

50. Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008; 158: 1345-1349.

51. Lee EJ, Shin MK, Kim NI. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol. 2010; 22:1 38-142.

52. Vena GA, Cassano N, Loconsole F, Guerra AP. Sequential treatment of psoriasis with infliximab followed by cyclosporin. Preliminary results of an open-label prospective study. G Ital Dermatol Venereol. 2008; 141: 221-225.

53. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007; 56: 598-603.

54. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. Br Med J (Clinical Research Ed.). 2010; 340: c147.

55. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005; 152: 1304-1312.

56. Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat. 2007; 18: 76-83.

57. Koc E, Tunca M, Akgul EO, Akar A, Kurt Y, Kurumlu Z et al. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study. J Dermatol. 2009; 36: 191-196.

58. Barrera MV, Habicheyn S, Mendiola MV, Herrera CE. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol. 2008; 18: 683-687.

59. Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health. 2008; 11: 400-407.

60. Griffiths CE et al. Response to retreatment with ustekinumab after withdrawal from therapy in patients with moderate to severe psoriasis: results from the PHOENIX 1 and ACCEPT phase 3 clinical trials (P55). Br J Dermatol. 2011; 165: 43.

61. Leonardi CL et al. The efficacy and safety of etanercept in the retreatment of psoriasis after relapse (P568). J Am Acad Dermatol. 2004: 146.

62. Ortonne JP, Taïeb A, Ormerod AD, Robertson D, Foehl J, Pedersen R et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol. 2009; 161: 1190-1195.

63. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007; 56: 31 (e1-15).

64. Papp K, Crowley J, Ortonne JP, Leu J, Okun M, Gupta SR et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol. 2011; 164: 434-441.

65. Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One. 2012; 7: e33486.

66. Vena G, Loconsole F, Mastrandrea V, Buquicchio R, Cassano N. Therapeutic hotline: re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis. Dermatol Ther. 2010; 23: 199-202.

67. Cassano N, Puglisi GA, Malara C, Loconsole F, Galluccio A, Pezza M et al. Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. Int J Immunopath & Pharmacol. 2007; 20: 647-650.

68. Cassano N, Loconsole F, Miracapillo A, Travaglini M, Digiuseppe MD, Congedo M et al. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Talpharanta Plastic Study Group. Int J Immunopath & Pharmacol. 2010; 23: 797-802.

69. Driessen RJB, Berends MAM, Boezeman JB, van de Kerkhof PC, de Jong EM. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. Br J Dermatol. 2008; 158: 1098-1106.

70. Perera G, Fonia A, Smith C, Barker JNWN. Etanercept in patients with moderate to severe plaque psoriasis: a retrospective case cohort analysis. Br J Dermatol. 2009; 161: 26-27.

71. Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S et al. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Int J Immunopath & Pharmacol. 2009; 22: 227-233.

72. Bissonnette R, Bolduc C, Poulin Y, Guenther L, Lynde CW, Maari C et al. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol. 2010; 63: 228-234.

73. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371: 1675-1684.

74. Pitarch G, Sánchez-Carazo JL, Mahiques L, Oliver V. Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology. 2008; 216: 312-316.

75. Haitz KA, Kalb RE. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol. 2007; 57: 120-125.

76. Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol. 2011; 67: 642-650.

77. Yamauchi PS, Mau N. Adalimumab treats psoriasis in patients previously treated with etanercept: A case series. J Am Acad Dermatol. 2009; 61: 158-160.

78. Griffiths EM, Strober BE, van de Kerkhof P, Roseanne FV, Yeilding N, Guzzo C et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Eng J Med. 2010; 362: 118-128.

79. Vender R. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. J Drugs Dermatol. 2011; 10: 396-402.

80. Downs AMR. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor α biologics and switched to ustekinumab. Br J Dermatol. 2010; 163: 433-434.

81. Martínez-Sahuquillo Amuedo ME, Echevarria Ruiz de Vargas MC. Métodos de consenso. Uso adecuado de la evidencia en la toma de decisiones. «Método RAND/UCLA». Rehabilitación. 2001; 35: 388-392.

82. Hutchings A, Raine R. A systematic review of factors affecting the judgments produced by formal consensus development methods in health care. J Health Serv Res Policy. 2006; 11: 172-179.